Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009

Br J Cancer. 2012 Nov 20;107(11):1810-4. doi: 10.1038/bjc.2012.462. Epub 2012 Oct 11.


Background: Post-molar pregnancy gestational trophoblastic tumours (GTT) have been curable with chemotherapy treatment for over 50 years. Because of the rarity of the diagnosis, detailed structured information on prognosis, treatment escalations and outcome is limited.

Methods: We have reviewed the demographics, prognostic variables, treatment course and clinical outcomes for the post-mole GTT patients treated at Charing Cross Hospital between 2000 and 2009.

Results: Of the 618 women studied, 547 had a diagnosis of complete mole, 13 complete mole with a twin conception and 58 partial moles. At the commencement of treatment, 94% of patients were in the FIGO low-risk group (score 0-6). For patients treated with single-agent methotrexate, the primary cure rate ranged from 75% for a FIGO score of 0-1 through to 31% for those with a FIGO score of 6.

Conclusion: In the setting of a formal follow-up programme, the expected cure rate for GTT after a molar pregnancy should be 100%. Prompt treatment and diagnosis should limit the exposure of most patients to combination chemotherapy. Because of the post-treatment relapse rate of 3% post-chemotherapy, hCG monitoring should be performed routinely.

MeSH terms

  • Adult
  • Chorionic Gonadotropin / blood
  • Female
  • Gestational Trophoblastic Disease / drug therapy*
  • Humans
  • Hydatidiform Mole / complications*
  • Leucovorin / therapeutic use
  • Methotrexate / therapeutic use
  • Pregnancy
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome


  • Chorionic Gonadotropin
  • Leucovorin
  • Methotrexate